Resverlogix Corp. (TSE:RVX – Get Free Report)’s share price hit a new 52-week low on Tuesday . The stock traded as low as C$0.04 and last traded at C$0.05, with a volume of 83000 shares trading hands. The stock had previously closed at C$0.04.
Resverlogix Stock Performance
The company has a quick ratio of 0.04, a current ratio of 0.13 and a debt-to-equity ratio of -10.95. The stock has a market capitalization of C$7.92 million, a P/E ratio of -1.98 and a beta of 0.71. The firm’s 50-day simple moving average is C$0.05 and its 200 day simple moving average is C$0.05.
About Resverlogix
Resverlogix Corp clinical-stage biotechnology company. The company is developing an advanced epigenetic drug called apabetalone for the treatment of patients with cardiovascular disease, diabetes mellitus, chronic kidney disease, peripheral artery disease, orphan diseases, and neurodegenerative diseases.
See Also
- Five stocks we like better than Resverlogix
- Why Special Dividends Can be a Delightful Surprise for Income Investors
- Beware of BigBear.ai: Insiders Are Selling—Should You?
- How to Choose Top Rated Stocks
- CrowdStrike Stock is a Buy as Cyberthreat Environment Expands
- How to trade using analyst ratings
- Congress! Who Traded What During the Tariff-Induced Meltdown
Receive News & Ratings for Resverlogix Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Resverlogix and related companies with MarketBeat.com's FREE daily email newsletter.
